Navigation Links
Nektar Therapeutics Reports Fourth Quarter and Year-End 2012 Financial Results
Date:2/28/2013

lude Baxter's BAX 855, a long-acting PEGylated rFVIII program, which is in Phase 3 clinical development.

Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India.  Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "expect," "believe," "should," "may," "will" and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding the potential future regulatory filings by AstraZeneca for naloxegol; the projected timing of the start of the Phase 3 clinical study by Bayer for Amikacin Inhale; the projected availability of Phase 2 clinical study results for NKTR-181; and the value and potential of our technology and research and development pipeline. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results to differ materially from th
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Nektar To Host Conference Call To Discuss The Positive Phase 3 Clinical Results For Naloxegol
2. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
3. Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets
4. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the UBS 2012 Global Life Sciences Conference in New York City
5. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012
6. Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
7. Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
8. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
9. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2012 Global Healthcare Conference in New York
10. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
11. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Oct. 21, 2014   BioNano Genomics , ... genomics research centers to purchase an Irys™ System ... National Cancer Institute (NCI), NIH Intramural Sequencing Center (NISC) ... Irys, obtaining a comprehensive view of a genome ... (NGS) does not deliver the scalability or reliability ...
(Date:10/22/2014)... 21, 2014 Abaxis, Inc. (NasdaqGS: ... analysis systems, today reported financial results for the second ... quarter overview: , Revenues of $53.9 million, up ... EPS of $0.24, up 33% over last year,s comparable ... from Abaxis Veterinary Reference Laboratories (AVRL) of $3.5 million, ...
(Date:10/22/2014)... WESTMINSTER, Colo. , Oct. 22, 2014   ... class of infusion systems designed to maximize targeted delivery ... is pleased to announce that oncologist John R. ... Norris Comprehensive Cancer Center, and surgical oncologist Steven ... Center have joined the Company,s Scientific Advisory Board (SAB).  ...
Breaking Medicine Technology:BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 2Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 4Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 5Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 6Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 7Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 8Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 9Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 10Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 11Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 12Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 13Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 14Surefire Medical's Scientific Advisory Board Expands, Broadens Clinical Trial Expertise 2
... 8 Mylan Inc. (Nasdaq: MYL ) today announced ... and license agreements with Wyeth, now part of Pfizer, relating ... 75 mg and 150 mg, the generic version of Wyeth,s ... Pursuant to the license agreement, Mylan will be granted a ...
... , BEVERLY ... pioneering medical opiate detoxification procedure, offers one of the ... technology to treat dependencies to Zolpidem, a prescription medication widely used ... including Ambien and Edluar. The Waismann Method of ...
Cached Medicine Technology:Mylan Announces Settlement Agreement Related to Antidepressant Effexor XR(R) 2Waismann Method Offers Safe and Alternative Treatment for Dependency to Ambien 2Waismann Method Offers Safe and Alternative Treatment for Dependency to Ambien 3
(Date:10/22/2014)... Mission Viejo, CA (PRWEB) October 22, 2014 ... that Jay Cormier, Sr. Vice President of Sales, will ... at the upcoming Meetings Technology Expo on October 28, ... will also be hosting a booth as well as ... on how Lintelus Meeting can create a more engaging ...
(Date:10/22/2014)... By Maureen Salamon ... -- Black women undergoing in vitro fertilization (IVF) are only ... using the popular assisted reproduction technique, new research indicates, and ... In the study, about 31 percent of white patients ... black patients. Analyzing more than 4,000 IVF cycles over ...
(Date:10/22/2014)... Measures taken by Firestone officials at the company,s ... the spread of the disease there and could prove ... Co. provides health services to about 80,000 employees, retirees, ... Between Aug. 1 and Sept. 23, there were ... people. That incidence rate of 0.09 percent was much ...
(Date:10/20/2014)... 2014 With a mere 19 days ... made a brief fundraising stop at the  Law ... Fresh from a debate last night with his opponent ... for the first seven minutes because Crist had an ... the incident in one word: "weird." , Before touching ...
(Date:10/20/2014)... Women’s health specialist, Dr. Amber Murphy, MD, Ob/Gyn ... Inc., A Division of MaternOhio Clinical Associates, Inc., who ... patients annually. Dr. Murphy will provide a full range ... women’s life. She is accepting new patients at two ... , Dr. Murphy offers a wide variety of services ...
Breaking Medicine News(10 mins):Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 2Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 3Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 2Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 3
... (HealthDay News) -- Feelings of shame, social isolation and rejection ... finds. The findings may help explain why depression is ... other kinds of cancer, according to the researchers at the ... association with tobacco use, lung cancer is commonly viewed as ...
... a key mechanism that causes breast cancer to spread. The ... journal Molecular Cell , enhances our knowledge about the ... for a lethal form of invasive breast cancer that is ... ErbB2 has been linked with aggressive forms of breast cancer ...
... irritable bowel syndrome (IBS) have a significantly greater prevalence ... as well as physical, emotional and sexual abuse, according ... Hepatology, the official journal of the American Gastroenterological ... associated with the development of irritable bowel syndrome, particularly ...
... most common kidney cancer subtype, face a low risk of ... key findings of a multi-centre study of nearly 600 patients ... BJUI . "Because papillary renal cell ... patients, the small number of patients enrolled in individual studies ...
... strategy includes a plan to ensure that General Practitioners (GPs) ... 23 March 2012, downloadable from http://www.homeoffice.gov.uk/publications/ ). There is ... The big question is, what should GPs say to their ... scientific journal Addiction analysed the advice given by ...
... PHILADELPHIA Patients with end-stage liver disease complicated by ... carcinoma (HCC) are less likely to die or ... a new liver than those with other complications of ... Perelman School of Medicine at the University of Pennsylvania. ...
Cached Medicine News:Health News:Stigma, Shame Can Worsen Depression in Lung Cancer Patients 2Health News:Researchers identify mechanism that makes breast cancer invasive 2Health News:Childhood traumatic experiences associated with adult IBS symptoms 2Health News:Kidney cancer subtype study finds low recurrence and cancer death rates 2Health News:Penn researchers call for a re-examination of transplant waitlist prioritization 2Health News:Penn researchers call for a re-examination of transplant waitlist prioritization 3
... Wrist Fixator is now available in a ... necessary instrumentation. The surgical technique is printed ... reference. , ,This fixator allows the surgeon ... making multipaner adjustments in the frame via ...
... The WristJack External Fixation System for ... palmar tilt, radial inclination, length and rotation. ... to place the wrist into extension without ... are easily performed in the surgeons office. ...
... slender design contributes to overall low-profile frame ... The Connecting Clamp allows connection of 3.0 ... Uses 3.0 mm Carbon Fiber Rods. The ... to predrill and provide more stability and ...
The DFS MiniFixator is a lightweight, external device for the treatment of small bone fractures and osteotomies....
Medicine Products: